Publication | Closed Access

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

76-Week ResultsImmunologyClinical TrialsClinical DermatologyPhoenix 1Placebo-controlled TrialDermatologyExperimental DermatologyImmunotherapyMedicine